Literature DB >> 12045689

Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone.

Vassilios A Paparizos, Kyriakos P Kyriakis, Vassilios Papastamopoulos, Maria Hadjivassiliou, Nikolaos G Stavrianeas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12045689     DOI： 10.1097/00042560-200206010-00015

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  13 in total

Review 1.  HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease.

Authors:  Ryan J Sullivan; Liron Pantanowitz; Corey Casper; Justin Stebbing; Bruce J Dezube
Journal:  Clin Infect Dis       Date:  2008-11-01       Impact factor: 9.079

Review 2.  When Global ART Budgets Cannot Cover All Patients, Who Should Be Eligible?

Authors:  Yi Zhang; Till Bärnighausen; Nir Eyal
Journal:  J Acquir Immune Defic Syndr       Date:  2019-06-01       Impact factor: 3.731

3.  High seroprevalence of antibodies against Kaposi's sarcoma-associated herpesvirus (KSHV) among HIV-1-infected children and adolescents in a non-endemic population.

Authors:  Cornelia Feiterna-Sperling; Christoph Königs; Gundula Notheis; Bernd Buchholz; Renate Krüger; Katharina Weizsäcker; Josef Eberle; Nikola Hanhoff; Barbara Gärtner; Harald Heider; Detlev H Krüger; Jörg Hofmann
Journal:  Med Microbiol Immunol       Date:  2016-05-30       Impact factor: 3.402

4.  The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro.

Authors:  Soren Gantt; Jacquelyn Carlsson; Minako Ikoma; Eliora Gachelet; Matthew Gray; Adam P Geballe; Lawrence Corey; Corey Casper; Michael Lagunoff; Jeffrey Vieira
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

Review 5.  Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis.

Authors:  Lyubomir A Dourmishev; Assen L Dourmishev; Diana Palmeri; Robert A Schwartz; David M Lukac
Journal:  Microbiol Mol Biol Rev       Date:  2003-06       Impact factor: 11.056

6.  Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response.

Authors:  Huong Q Nguyen; Amalia S Magaret; Mari M Kitahata; Stephen E Van Rompaey; Anna Wald; Corey Casper
Journal:  AIDS       Date:  2008-05-11       Impact factor: 4.177

Review 7.  Liposomal daunorubicin as treatment for Kaposi's sarcoma.

Authors:  Christin E Petre; Dirk P Dittmer
Journal:  Int J Nanomedicine       Date:  2007

Review 8.  Human herpesvirus 8--a novel human pathogen.

Authors:  Daniel C Edelman
Journal:  Virol J       Date:  2005-09-02       Impact factor: 4.099

9.  Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy.

Authors:  V Martinez; E Caumes; L Gambotti; H Ittah; J-P Morini; J Deleuze; I Gorin; C Katlama; F Bricaire; N Dupin
Journal:  Br J Cancer       Date:  2006-04-10       Impact factor: 7.640

10.  Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune reconstitution syndrome related Kaposi sarcoma.

Authors:  Liviu Feller; Johan Lemmer
Journal:  Infect Agent Cancer       Date:  2008-01-21       Impact factor: 2.965
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.